Eplerenone
25 mg · Tablet, Coated
- Prescription only
- Aldosterone Antagonist
- Active substance
- Eplerenone
- Made by
- Westminster Pharmaceuticals, LLC
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Inspra). It describes the substance, not this exact product.
Eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone, a component of the renin-angiotensin-aldosterone-system (RAAS).
Aldosterone synthesis, which occurs primarily in the adrenal gland, is modulated by multiple factors, including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone (ACTH) and potassium.
Metabolism and Excretion Eplerenone metabolism is primarily mediated via CYP3A4.
Following a single oral dose of radiolabeled drug, approximately 32% of the dose was excreted in the feces and approximately 67% was excreted in the urine.
Absorption is not affected by food.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-06-23
Safety of the active substance
From the US prescribing label for the same active substance (Inspra). It describes the substance, not this exact product.
- For All Patients INSPRA is contraindicated in all patients with:. serum potassium >5.5 mEq/L at initiation,. creatinine clearance ≤30 mL/min, or. concomitant administration of strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir) [see Drug Interactions (7.1), Clinical Pharmacology (12.3) ].
- Serum potassium >5.5 mEq/L at initiation ( 4 ).
- Creatinine clearance ≤30 mL/min ( 4 ).
- Concomitant use with strong CYP3A inhibitors ( 4, 7.1 ) For the treatment of hypertension:.
Most common adverse reactions (>2% and more frequent than with placebo): hyperkalemia and increased creatinine.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
Details
| Made by | Westminster Pharmaceuticals, LLC |
|---|---|
| Active substance | Eplerenone |
| Used in | Heart, blood pressure and circulation |
| Strength | 25 mg |
| Form | Tablet, Coated |
| Route | Oral |
| Packs | 90 TABLET, COATED in 1 BOTTLE, PLASTIC · 30 TABLET, COATED in 1 BOTTLE, PLASTIC |
| NDC | 69367-307 |
Source: NDC Directory · 2026-09-13 · not reviewed by a clinician
Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).
Other strengths and forms
19 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- Tablet, Film Coated10 products
- Tablet, Coated7 products
25 mg4
25 mg · 4 companies
- AvKARE
- Bryant Ranch Prepack
- Proficient Rx LP
- Westminster Pharmaceuticals, LLC · this page
50 mg3
50 mg · 3 companies
- Tablet2 products
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.